Before worrying about positioning new and subsequent therapies in moderate to severe ulcerative colitis, plan for the patient’s first biologic drug to be “forever” – that’s the advice from Professor John Marshall . Speaking at AGW 2019, the director of gastroenterology at Canada’s McMaster University said bio-naive patients were the most responsive. “Protect and optimise ...
Already a member?
Enter your email to keep reading.